Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 421 to 435 of 1243 results for public health guidance

  1. NICE voluntary and community sector forum

    Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.

  2. What lay members do

    to a member of one of our committees who has personal experience of using health or care services. The phrase could also refer to...

  3. What lay members do

    to a member of one of our committees who has personal experience of using health or care services. The phrase could also refer to...

  4. Ensitrelvir for treating COVID-19 [ID6231]

    Awaiting development Reference number: GID-TA11224 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

    Awaiting development Reference number: GID-TA11342 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

    Awaiting development Reference number: GID-TA11094 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732]

    In development Reference number: GID-TA11959 Expected publication date:  17 June 2027

    Technology appraisal guidance
    In development

  8. Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]

    In development Reference number: GID-TA11958 Expected publication date:  21 April 2027

    Technology appraisal guidance
    In development

  9. Software with artificial intelligence (AI)-derived algorithms to help interpret electroencephalograms (EEGs) for suspected epilepsy: early-use assessment: draft guidance

    We are listening to your views on this HealthTech guidance. Comments close 30 June 2026.

    In consultation

  10. Dupilumab for treating bullous pemphigoid [ID6479]

    Awaiting development Reference number: GID-TA11615 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]

    Awaiting development Reference number: GID-TA11639 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Camizestrant as an add-on to a first-line CDK4/6 inhibitor for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation [ID6535]

    Awaiting development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Artificial intelligence (AI) technologies to help detect prostate cancer on MRI

    In development Reference number: GID-HTE10089 Expected publication date:  12 November 2026

    In development

  14. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development Reference number: GID-TA10832 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date:  04 September 2026

    Technology appraisal guidance
    In development